Resource Center

Filter By:
View As:
Content type
Resouce type
Topic
Show more
Sort By:

Speed to patient is a primary driver behind the industry’s shift toward modern commissioning and qualification (C&Q) practices, while still ensuring product quality and...

As capital projects and technology transfers wrap up and facilities grow nearer to startup, site leaders and team members may be filled with a...

The 2023 revision of EU GMP Annex 1 reset the global standard for sterile manufacturing. It expands the guidance, tightens contamination-control expectations and aligns...

The Windsor Framework (WF), which came into effect on January 1, 2025, is a significant agreement between the UK and the EU that replaces...

August 11, 2025 – Indianapolis, IN — CAI, a global leader in operational readiness and excellence for high-stakes, regulated environments, is proud to announce...

A small-scale parenteral nutritional compounding facility in Europe engaged CAI to support remediation efforts required by its local Regulatory Authority. The client site had...

In 2008, the FDA issued guidance exempting most Phase 1 investigational drugs from the full scope of Title 21 of the Code of Federal...

CAI partnered with pharmaceutical manufacturers to deliver multiple aseptic fill lines across global sites....
The CAI team utilized our operational readiness (OR) approach to provide a wide range of support for a client who was on a challenging...

New email domain, same CAI. We’re updating our emails to match our web domain. Full transition by October 3.